[go: up one dir, main page]

DE68901098D1 - Zusammensetzung aus antikoagulantia. - Google Patents

Zusammensetzung aus antikoagulantia.

Info

Publication number
DE68901098D1
DE68901098D1 DE8989100852T DE68901098T DE68901098D1 DE 68901098 D1 DE68901098 D1 DE 68901098D1 DE 8989100852 T DE8989100852 T DE 8989100852T DE 68901098 T DE68901098 T DE 68901098T DE 68901098 D1 DE68901098 D1 DE 68901098D1
Authority
DE
Germany
Prior art keywords
anticoagulant
anticoagulantia
composition
activity
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE8989100852T
Other languages
English (en)
Inventor
Keizo Hirahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11897770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68901098(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of DE68901098D1 publication Critical patent/DE68901098D1/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/4866Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8989100852T 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia. Revoked DE68901098D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63015761A JP2739050B2 (ja) 1988-01-28 1988-01-28 抗血液凝固剤

Publications (1)

Publication Number Publication Date
DE68901098D1 true DE68901098D1 (de) 1992-05-07

Family

ID=11897770

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8989100852T Revoked DE68901098D1 (de) 1988-01-28 1989-01-19 Zusammensetzung aus antikoagulantia.

Country Status (13)

Country Link
US (1) US5084273A (de)
EP (1) EP0326014B1 (de)
JP (1) JP2739050B2 (de)
KR (1) KR0127754B1 (de)
AT (1) ATE74273T1 (de)
AU (1) AU607303B2 (de)
CA (1) CA1330299C (de)
DE (1) DE68901098D1 (de)
DK (1) DK37789A (de)
ES (1) ES2039709T3 (de)
GR (1) GR3005040T3 (de)
IE (1) IE63528B1 (de)
PT (1) PT89534B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
WO1994002172A1 (en) 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
KR100330540B1 (ko) * 1993-04-05 2002-09-04 웰파이드 코포레이션 안티트롬빈-iii액상제제및그안정화방법
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
AU2467395A (en) * 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
JPH08224227A (ja) * 1995-02-22 1996-09-03 Internatl Reagents Corp 血液採血管
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
EA004881B1 (ru) * 1997-04-28 2004-08-26 Эли Лилли Энд Компани Лиофилизированные композиции на основе рекомбинантного человеческого активированного протеина с и их применение
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
CA2410567A1 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
US20030055003A1 (en) * 2001-07-19 2003-03-20 David Bar-Or Use of copper chelators to inhibit the inactivation of protein C
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
EP2543380B1 (de) * 2008-01-29 2016-11-23 Kyowa Hakko Kirin Co., Ltd. Mittel zur förderung des wachstums von neuralen stammzellen
KR20250036821A (ko) 2022-07-01 2025-03-14 위니베르시테이트 마스트리흐트 음으로 하전된 다당류 및 프로테아제의 복합체에 의한 히스톤 세포독성의 개선된 하향조절

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds

Also Published As

Publication number Publication date
KR890011606A (ko) 1989-08-21
JPH01193229A (ja) 1989-08-03
EP0326014B1 (de) 1992-04-01
IE63528B1 (en) 1995-05-03
IE890269L (en) 1989-07-28
GR3005040T3 (de) 1993-05-24
DK37789A (da) 1989-07-29
EP0326014A1 (de) 1989-08-02
US5084273A (en) 1992-01-28
ATE74273T1 (de) 1992-04-15
AU2885589A (en) 1989-08-03
ES2039709T3 (es) 1993-10-01
JP2739050B2 (ja) 1998-04-08
PT89534B (pt) 2001-05-31
AU607303B2 (en) 1991-02-28
CA1330299C (en) 1994-06-21
DK37789D0 (da) 1989-01-27
PT89534A (pt) 1989-10-04
KR0127754B1 (ko) 1998-04-01

Similar Documents

Publication Publication Date Title
DE68901098D1 (de) Zusammensetzung aus antikoagulantia.
DE3880047D1 (de) Zusammensetzung eines zusatzes.
SE8000469L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
FI904230A0 (fi) Akrylsyraderivat.
MY104685A (en) Substituted thiazoles and their use as fungicides.
KR870700005A (ko) 하나이상의 활성성분을 함유하는 살충제 조성물
NO166871C (no) Termoplastiske blandinger.
IT8421273A0 (it) Derivati furanici con attivita'antiulcera.
ES2038714T3 (es) Mezclas de substancias activas fungicidas.
IT8447964A1 (it) Complessi d'inclusione, loro preparazione e loro impiego come insetticidi.
DE3871036D1 (de) Leistungsregelung von kombianlagen.
DE68907083D1 (de) Abkoemmlinge von 2-cyclopentenon.
ES2000033A6 (es) Composicion de bitionol sulfoxido porcedimiento para su fabricacion y metodo de utilizacion de aquella
DK191089A (da) Biologisk aktive forbindelser
ATE44640T1 (de) Schaedlingsbekaempfungsmittel.
DE3675069D1 (de) Carboxanilide.
IT8021337A0 (it) Nuove frazioni di eparina dotate di maggiore attivita' anticoagulante e procedimento per ottenerle.
CA2000153A1 (en) Antidote
ES2125849T3 (es) 1-dimetilcarbamoil-3-sustituido-5-sustituido-1h-1,2,4-triazoles.
DK44184D0 (da) Kosmetik
ES8707706A1 (es) Un procedimiento para la preparacion de nuevos derivados de propanodiona.
FI872869A0 (fi) Foerfarande foer stabilisering av enzymet laktoperoxidas i produkter.
DE68913797D1 (de) Verwendung von Paraaminosalicylsäure zur Stabilisierung der enzymatischen Aktivität von Peroxydase in Lösung, Stabilisierungsmittel und Verwendung von stabiliserter Lösung.
DE69909010D1 (de) Verwendung von procyanidolischen Oligomeren oder Anthocyanosiden als Anti-Urease Wirkstoffe

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation